Efficacy of a glucose meter connected to a mobile app on glycemic control and adherence to self-care tasks in patients with T1DM and LADA: a parallel-group, open-label, clinical treatment trial.

Arch Endocrinol Metab · 2021 · PMC10065322 · PMID 33905630

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

showed a trendp = 0.05actually significant

Group A compared with Group B + C showed a trend (p = 0.05) toward more patients with > 70% of blood glucose levels in the target range (70–180 mg/dL) in the first focus week.

also in 47,116 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.